PMID- 36116207
OWN - NLM
STAT- MEDLINE
DCOM- 20221025
LR  - 20221025
IS  - 1898-4002 (Electronic)
IS  - 1896-1126 (Linking)
VI  - 67
IP  - 2
DP  - 2022 Sep
TI  - The modulatory role of dendritic cell-T cell cross-talk in breast cancer: 
      Challenges and prospects.
PG  - 353-363
LID - S1896-1126(22)00035-9 [pii]
LID - 10.1016/j.advms.2022.09.001 [doi]
AB  - Antigen recognition and presentation are highlighted as the first steps in 
      developing specialized antigen responses. Dendritic cells (DCs) are outstanding 
      professional antigen-presenting cells (APCs) responsible for priming cellular 
      immunity in pathological states, including cancer. However, the diminished or 
      repressed function of DCs is thought to be a substantial mechanism through which 
      tumors escape from the immune system. In this regard, DCs obtained from breast 
      cancer (BC) patients represent a notably weakened potency to encourage specific 
      T-cell responses. Additionally, impaired DC-T-cell cross-talk in BC facilitates 
      the immune evade of cancer cells and is connected with tumor advancement, immune 
      tolerance, and adverse prognosis for patients. In this review we aim to highlight 
      the available knowledge on DC-T-cell interactions in BC aggressiveness and show 
      its therapeutic potential in BC treatment.
CI  - Copyright (c) 2022 Medical University of Bialystok. Published by Elsevier B.V. All 
      rights reserved.
FAU - Shahverdi, Mahshid
AU  - Shahverdi M
AD  - Department of Medical Biotechnology, Arak University of Medical Sciences, Arak, 
      Iran.
FAU - Masoumi, Javad
AU  - Masoumi J
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Ghorbaninezhad, Farid
AU  - Ghorbaninezhad F
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Department of Immunology, Faculty of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Shajari, Neda
AU  - Shajari N
AD  - Department of Immunology, School of Medicine, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
FAU - Hajizadeh, Farnaz
AU  - Hajizadeh F
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Hassanian, Hamidreza
AU  - Hassanian H
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Alizadeh, Nazila
AU  - Alizadeh N
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Jafarlou, Mahdi
AU  - Jafarlou M
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Baradaran, Behzad
AU  - Baradaran B
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Department of Immunology, Faculty of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran. Electronic address: baradaranb@tbzmed.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220915
PL  - Netherlands
TA  - Adv Med Sci
JT  - Advances in medical sciences
JID - 101276222
SB  - IM
MH  - Humans
MH  - Female
MH  - *T-Lymphocytes
MH  - *Breast Neoplasms
MH  - Dendritic Cells
OTO - NOTNLM
OT  - Breast cancer
OT  - Dendritic cell
OT  - Immune surveillance
OT  - Immunotherapy
OT  - T lymphocyte
COIS- Declaration of competing interest The authors declare no conflict of interests.
EDAT- 2022/09/19 06:00
MHDA- 2022/10/26 06:00
CRDT- 2022/09/18 18:10
PHST- 2022/05/01 00:00 [received]
PHST- 2022/07/05 00:00 [revised]
PHST- 2022/09/04 00:00 [accepted]
PHST- 2022/09/19 06:00 [pubmed]
PHST- 2022/10/26 06:00 [medline]
PHST- 2022/09/18 18:10 [entrez]
AID - S1896-1126(22)00035-9 [pii]
AID - 10.1016/j.advms.2022.09.001 [doi]
PST - ppublish
SO  - Adv Med Sci. 2022 Sep;67(2):353-363. doi: 10.1016/j.advms.2022.09.001. Epub 2022 
      Sep 15.